MEMPHIS, TN – In a landmark study that promises to redefine post-treatment care for a vulnerable population, scientists at St. Jude Children’s Research Hospital have unveiled a critical insight: the risk of secondary cancers in childhood cancer survivors is a complex interplay of both their lifesaving initial treatments and their inherent genetic makeup. This groundbreaking research, published today in the prestigious journal The Lancet Oncology, marks the first time experts have precisely quantified the proportional contributions of these factors at a population level, offering a clearer roadmap for prevention, early detection, and personalized care.
For long-term survivors of childhood cancer, the battle doesn’t necessarily end with remission. Secondary cancers emerge as the primary cause of mortality, casting a long shadow over lives that have already endured immense hardship. Historically, the focus has predominantly been on the adverse effects of intensive cancer therapies. While these treatments are undeniably crucial for survival, the new findings from St. Jude emphasize that a survivor’s genetic predisposition plays an equally, and sometimes even more, significant role than previously understood, particularly when compared to certain chemotherapy regimens.
"We found the burden of second cancer in survivors of childhood cancer is largely contributed by pediatric treatment exposures and genetic predisposition," stated Dr. Yadav Sapkota, corresponding author and a distinguished member of the St. Jude Department of Epidemiology and Cancer Control. "We’ve known treatment exposures and genetics were associated with second cancer risk, but this is the first time we’ve been able to attribute the proportion of their contributions to that risk at the population level." This quantification represents a pivotal shift, moving beyond mere association to precise attribution, a development with profound implications for clinical practice and patient advocacy.
A Shifting Paradigm: From Association to Attribution
The journey to understanding secondary cancer risk in childhood cancer survivors has been a progressive one, evolving over decades as medical science advanced and survivor cohorts grew.
The Historical Lens: Focus on Treatment Toxicity
For many years, the prevailing understanding of secondary cancer risk largely centered on the cytotoxic nature of cancer treatments themselves. Oncologists and researchers meticulously documented the long-term adverse effects of radiation therapy and various chemotherapy agents, recognizing their potential to damage healthy cells and DNA, thereby increasing the likelihood of new malignancies later in life. Early research primarily examined these factors in isolation, meticulously cataloging the associations between specific types of treatment, dosages, and the incidence of particular secondary cancers. This foundational work was invaluable, leading to significant advancements in treatment protocols aimed at minimizing toxicity while maintaining efficacy. For instance, the recognition of radiation’s profound long-term impact spurred efforts to reduce radiation doses or, where possible, eliminate its use in favor of other effective treatments.
Addressing the Knowledge Gap: The Need for Proportional Contributions
Despite the wealth of data linking treatment exposures to increased risk, a crucial piece of the puzzle remained elusive: the relative contribution of each factor—treatment, genetics, and even lifestyle—at a population level. While it was clear that each played a role, the precise weight of their influence had never been empirically determined. This knowledge gap posed a challenge for clinicians striving to offer truly personalized risk assessments and preventative strategies. Without understanding the proportional contributions, interventions might not be optimally targeted, potentially overemphasizing one factor while underestimating another.
It was this critical void that scientists at St. Jude Children’s Research Hospital set out to address. Leveraging their unparalleled resources and expertise, they embarked on an ambitious study designed to disentangle these complex relationships. The St. Jude team recognized that a comprehensive, population-level analysis was essential to move beyond individual associations to a more holistic understanding of multifactorial risk.
The Genesis of a Groundbreaking Study
The impetus for this research stemmed from St. Jude’s unique position at the forefront of childhood cancer research and survivorship studies. The institution houses two of the world’s premier cohorts: the St. Jude Lifetime Cohort Study (St. Jude LIFE) and the Childhood Cancer Survivor Study (CCSS). These studies collectively represent the largest survivor cohort in North America, providing an extraordinary repository of longitudinal data. The St. Jude LIFE study meticulously follows former St. Jude patients throughout their adult lives, documenting their health outcomes, treatment exposures, and genetic profiles. Similarly, the CCSS, a multi-institutional collaboration led by St. Jude, tracks a vast cohort of childhood cancer survivors from numerous treatment centers across the U.S. and Canada.
Together, these cohorts encompass over 10,000 survivors, with more than 12,000 participants having undergone genetic sequencing. This immense dataset provided an unprecedented opportunity to integrate a wide array of information, including detailed records of initial cancer treatments (types of chemotherapy, radiation fields and doses), comprehensive genetic information (both common and rare variants), and various lifestyle factors. This meticulous data collection allowed researchers to evaluate the nuanced contributions of each element to the occurrence of subsequent primary cancers.
Dr. Greg Armstrong, MD, MSCE, chair of the St. Jude Department of Epidemiology and Cancer Control and a co-author of the study, underscored the unparalleled nature of this resource: "This kind of high-impact discovery is only possible in the CCSS and SJLIFE cohorts, that in combination, have more than 12,000 survivors with genetic sequencing." The sheer scale and depth of these combined cohorts were indispensable in providing the statistical power and comprehensive data necessary to conduct such a complex, population-level attribution analysis.
Deconstructing Risk: The Supporting Data
The St. Jude study meticulously parsed the contributions of various factors to secondary cancer risk, revealing both expected and surprising insights. The findings paint a detailed picture of how treatment, genetics, and lifestyle each weigh into the equation.
Radiation: The Dominant, Yet Diminishing, Culprit
Consistent with prior research, radiation exposure emerged as the most significant single contributor to secondary cancer risk. The study quantified its impact, attributing approximately 40% or more of the overall risk to radiation therapy. This finding reinforces the long-standing understanding of radiation’s potent carcinogenic effects, which can persist for decades after treatment. Radiation works by damaging DNA in cancer cells, but it inevitably affects healthy surrounding tissues, increasing their susceptibility to malignant transformation over time.
However, this substantial contribution also carries a silver lining. The adverse long-term effects of radiation have been well-documented for years, prompting a proactive evolution in modern pediatric oncology. Contemporary treatment protocols have already seen a concerted effort to reduce radiation doses whenever possible, to narrow radiation fields, and even to remove radiation entirely from treatment regimens as other therapies, such as targeted agents and immunotherapies, have become more effective. The St. Jude study provides further robust evidence supporting these ongoing shifts in clinical practice, validating the prudence of minimizing radiation exposure in childhood cancer treatment. This data serves as a powerful endorsement for continued innovation in less toxic therapies.
The Nuanced Dance: Genetics vs. Chemotherapy
While radiation’s impact was relatively straightforward and largely confirmed existing knowledge, the researchers uncovered more complex and revealing relationships concerning chemotherapy and genetic predisposition.
Chemotherapy’s Variable Role: The study found that chemotherapy contributed between 8% and 35% of subsequent cancer risk, with the proportion varying significantly depending on the specific type of secondary cancer. This variability highlights the diverse mechanisms of action and toxicity profiles of different chemotherapeutic agents. Some classes of chemotherapy are known genotoxins, directly damaging DNA and increasing mutation rates, while others may exert their effects through different pathways. While the potential late effects of chemotherapy have been extensively described in previous literature, this study added a critical quantitative dimension, allowing for a more precise understanding of its population-level impact.
The Underestimated Power of Genetics: Perhaps the most striking finding was the substantial and often underestimated contribution of genetic predisposition to secondary cancer risk. The study revealed that, depending on the cancer type, polygenic risk scores (PRS) alone contributed to 5% to 37% of the risk. This finding challenges conventional wisdom and underscores the need for a paradigm shift in how risk is assessed.
To understand this predisposition, the researchers went beyond simple family history. They meticulously analyzed hundreds of common genetic variants previously associated with cancer development in the general population, integrating them into a polygenic risk score. They also examined the role of certain rare genetic variants. This sophisticated genetic analysis, applied to the vast St. Jude LIFE and CCSS cohorts, allowed them to discern the relationship between these genetic markers and the incidence of secondary cancers.
Dr. Yutaka Yasui, PhD, also from the St. Jude Department of Epidemiology and Cancer Control and a co-author, elaborated on the utility of this approach: "Polygenic risk scores are developed for all kinds of diseases for personalized medicine, but generally with precision below what is required for clinical utility in the general population. Among survivors of childhood cancer and for estimating their risk of certain types of subsequent cancer, however, they may provide useful information in conjunction with therapy exposures." This statement highlights that while PRS might have limitations in predicting risk for the general population, their predictive power becomes significantly more potent and clinically relevant when integrated with detailed treatment histories in a high-risk group like childhood cancer survivors.
The profound implication of these genetic findings was succinctly captured by Dr. Sapkota: "Our findings showed that genetics can be equally or more important than chemotherapy in some second cancers, which is counter to conventional wisdom in the field." This statement signals a major shift in understanding, suggesting that the intrinsic genetic vulnerabilities of an individual can be as, or even more, influential than the cytotoxic agents they received during treatment, particularly for certain types of subsequent malignancies. This challenges the long-held belief that treatment exposures overwhelmingly dominate the risk profile.
Lifestyle Factors: A Developing Story
In contrast to radiation, chemotherapy, and genetics, lifestyle factors—such as diet and exercise—appeared to contribute much less to secondary cancer risk in this particular study, accounting for a modest 1% to 6% of the risk. This finding, while initially surprising, comes with an important caveat. The survivors included in this study were primarily in their 20s and 30s. At this relatively young age, the long-term cumulative effects of lifestyle choices on cancer development may not yet have had sufficient time to manifest. Many lifestyle-related cancers typically develop over decades, and the study’s cohort may simply be too young to fully capture this impact.
Dr. Sapkota emphasized this point, clarifying the scope and limitations of this specific finding: "We know healthy lifestyle choices are important for survivors. In this study, we focused only on the risk of second cancers, which may not be strongly impacted by lifestyle at this young age. However, other research has shown the benefits of healthy choices on other late effects, such as protecting cardiac wellbeing, so it is still important for clinicians to encourage — and patients to seek — a healthy lifestyle." This nuanced perspective underscores that while lifestyle’s direct contribution to secondary cancer risk might appear modest in this specific cohort and timeframe, its overall importance for the holistic health and wellbeing of survivors remains undeniable. It also suggests that future longitudinal studies following survivors into older age may reveal a more pronounced role for lifestyle factors.
Official Responses and Expert Perspectives
The publication of these findings in The Lancet Oncology has elicited significant responses from the research team, underscoring the transformative potential of their work. The collective voices from St. Jude highlight the critical need for a more integrated approach to survivor care.
Dr. Yadav Sapkota, as the corresponding author, has been at the forefront of articulating the study’s impact. His emphasis on the quantification of risk factors resonates deeply within the medical community. "Historically, we have paid attention to survivors’ treatment exposures when determining second cancer risk," Sapkota noted, reflecting on past practices. "Our study suggests that we need to better account for genetic predisposition in this population." This statement is not merely a suggestion but a call to action, urging a re-evaluation of current risk assessment protocols. His words underscore the necessity of moving beyond a singular focus on treatment history to embrace a more comprehensive understanding that incorporates an individual’s intrinsic genetic vulnerabilities.
Dr. Greg Armstrong, a co-author and a leading figure in the field of pediatric cancer epidemiology, provided crucial context regarding the unique capabilities that enabled this discovery. His assertion that "This kind of high-impact discovery is only possible in the CCSS and SJLIFE cohorts, that in combination, have more than 12,000 survivors with genetic sequencing," speaks volumes about the institutional commitment and the sheer scale of data infrastructure at St. Jude. It highlights that such intricate, population-level analyses require an unprecedented depth of information, marrying extensive clinical histories with detailed genetic profiles—a feat few institutions globally can achieve. His statement also serves as a testament to the foresight of St. Jude and its collaborators in establishing and maintaining these invaluable survivor cohorts for decades.
Dr. Yutaka Yasui, another key co-author, shed light on the sophisticated methodology behind the genetic findings, particularly the application of polygenic risk scores (PRS). While acknowledging the general limitations of PRS for broad clinical utility in the general population, Dr. Yasui emphasized their enhanced relevance for childhood cancer survivors. "Among survivors of childhood cancer and for estimating their risk of certain types of subsequent cancer, however, they may provide useful information in conjunction with therapy exposures," he explained. This distinction is critical, suggesting that in a high-risk population already subjected to potent carcinogens, genetic predispositions act as powerful amplifiers, making PRS a more precise and actionable tool for personalized risk assessment. His perspective underscores that the value of genetic information is often context-dependent, reaching its full potential when integrated with other significant risk factors.
Collectively, these expert responses articulate a unified vision: that the future of care for childhood cancer survivors must be characterized by a more nuanced, personalized, and genetically informed approach. The study’s findings are not merely academic; they are a direct challenge to conventional wisdom and a powerful impetus for clinical transformation.
Implications: Reshaping the Future of Survivor Care
The profound insights generated by this St. Jude study are poised to trigger a significant re-evaluation of how childhood cancer survivors are monitored and managed throughout their lives. The implications extend across clinical practice, future research, and public health initiatives.
Changing Clinical Practice: Towards Personalized Surveillance
Perhaps the most immediate and impactful implication lies in the potential to revolutionize clinical guidelines for survivor follow-up. Dr. Sapkota’s call to "better account for genetic predisposition" suggests a shift from a largely uniform surveillance strategy, based primarily on treatment history, to a more personalized approach.
- Tailored Screening Protocols: Individuals identified with a strong genetic predisposition to specific secondary cancers, through advanced genetic screening techniques like polygenic risk scores, could receive more regular and intense cancer screenings. For example, a survivor with a high genetic risk for breast cancer, combined with a history of chest radiation, might warrant earlier and more frequent mammograms or MRIs compared to a survivor with similar treatment history but lower genetic risk. This targeted approach could lead to earlier detection of secondary cancers, when they are more likely to respond to treatment, thereby improving prognosis and survival rates.
- Integrated Risk Assessment: Clinicians will need to integrate genetic counseling and testing more seamlessly into long-term survivor care. This means not just reviewing treatment records but also assessing family history in greater detail and, where appropriate, offering germline genetic testing or polygenic risk scoring to better stratify individual risk. This holistic view will empower healthcare providers to make more informed decisions about surveillance intensity and type.
- Patient Empowerment and Advocacy: Survivors armed with a clearer understanding of their unique combination of treatment-related, genetic, and lifestyle risk factors will be better equipped to engage with their healthcare providers. They can more effectively advocate for the need for specific screenings, discuss their concerns, and participate actively in their own long-term health management. This knowledge can transform patients from passive recipients of care into informed partners in their health journey.
Driving Future Research and Development
The study also lays fertile ground for a new generation of research questions and initiatives:
- Validation and Refinement of PRS: Further studies are needed to validate polygenic risk scores in diverse survivor populations, including those from various ethnic backgrounds, to ensure their generalizability and clinical utility across all groups. Research could also focus on refining these scores by identifying additional genetic variants or improving the weighting of existing ones.
- Longitudinal Lifestyle Studies: While lifestyle factors showed a modest contribution in this young cohort, future longitudinal studies following survivors into older age are crucial to fully understand the delayed impact of diet, exercise, smoking, and other lifestyle choices on secondary cancer risk.
- Prevention Strategies: With a more precise understanding of genetic predispositions, researchers can explore novel prevention strategies, including chemoprevention or lifestyle interventions specifically targeted at high-risk genetic subgroups.
- Biomarker Discovery: The study could spur efforts to discover new biomarkers that predict secondary cancer development, allowing for even earlier detection and intervention.
A Public Health Imperative
Ultimately, the St. Jude findings underscore a critical public health imperative. "Second cancers remain the leading cause of mortality for childhood cancer survivors," Dr. Sapkota reiterated. "Now that we have quantified the contributions of treatment, genetics and lifestyle to the risk of secondary disease, we have a better understanding of where to focus efforts to prevent, detect and treat these cancers, and hopefully extend these survivors’ lives." This profound statement encapsulates the overarching goal: to translate scientific discovery into tangible improvements in the quality and length of life for childhood cancer survivors. By identifying the key drivers of secondary cancer, the medical community can allocate resources more effectively, develop more targeted interventions, and ultimately fulfill the promise of a healthier, longer life for those who have already triumphed over a life-threatening illness.
This pivotal research reaffirms St. Jude Children’s Research Hospital’s unwavering commitment to not only curing childhood cancer but also ensuring that survivors live full, healthy lives free from the specter of subsequent disease. It represents a beacon of hope, illuminating a clearer path forward in the complex landscape of survivorship care.
Authors and Funding
The study’s first author is Achal Neupane, of St. Jude. The study’s other authors are Siddhant Taneja, Jennifer French, Matthew Ehrhardt, Tara Brinkman, Rachel Webster, Jun Yang, Kirsten Ness, Melissa Hudson, Gregory Armstrong, Leslie Robison and Yutaka Yasui; St. Jude; Qi Liu; University of Alberta; Cindy Im, Lucie Turcotte and Joseph Neglia; University of Minnesota; Monica Gramatges, Baylor College of Medicine; Rebecca Howell, University of Texas MD Anderson Cancer Center and Smita Bhatia; University of Alabama at Birmingham.
The study was supported by grants from the National Cancer Institute (R01HL173881, R01CA216354, R21CA261833, U24CA55727, U01CA195547 and CA21765) and ALSAC, the fundraising and awareness organization of St. Jude.
About the Author
